|
|
|
| Analysis of the medication situation of neuroprotective agents from 2010 to 2015 in 6 cities of our country |
| WANG Huiyuan YANG Li ZHAO Zhigang▲ |
| Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China |
|
|
|
Abstract Objective To study the neuroprotective agents utilization in 6 cities (Beijing, Tianjin, Shanghai, Guangzhou, Hangzhou, Chengdu) of China from 2010 to 2015, in order to provide basis for promoting the rational use of drugs and medical resources. Methods "Hospital prescription analysis cooperation project" was used for data collection. The average daily cost value (DDDc), drug utilization index (DUI), serial number ratio (B/A value) and medication combination were calculated. Results The drugs that ranked in the front of DDDc were basically similar kinds in different regions. Those drugs were all general types, including Brain Nucleoside Carnosine, Edaravone, Ganglioside, Fasudil and Mouse Nerve Growth Factor. These drugs were frequently used with high cost and heavy economic burden. There were 3 kinds of drugs with the DUI > 1.0, which were Gangliosides, Mouse Nerve Growth Factor and Deproteinized Calf blood Serum. These drugs were excessive use in clinic and they were not rational used. The neuroprotective agents were most given by the single way, the double combination therapy had increased from 5.29% in 2010 to 14.89% in 2015. Conclusion There are excessive use of neuroprotective agents in these regions. The rational use of neuroprotective agents is deserved more attention.
|
|
|
|
|
|
[1] Demaerschalk BM，Hwang HM，Leung G. US cost burden of ischemic stroke：a systematicliterature review [J]. Am J Manag Care，2010，16（7）：525–533.
[2] 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识组.他汀类药物防治缺血性卒中/短暂性脑缺血发作专家共识[J].中国卒中杂志，2013，8（7）：565-575.
[3] Munson T，Sepideh AH. Neuroprotectant Drug Shows Promise in Human Ischemic Stroke [J]. World Neurosurg，2013，79（3/4）：408-411.
[4] Antonino T，Rosaria P，Valentina A，et al. Developing drug strategies for the neuroprotective treatment of acute isch?鄄emic stroke [J]. Exp Rev Neurother，2015，15（11）：1271-1284.
[5] Fisher M，Feuerstein G，Howells DW，et al.Updateof the stroke therapy academic industry roundtable preclinical recommendations [J]. Stroke，2009，40（6）：2244- 2250.
[6] 邹桢.舒血宁联合尼莫地平治疗急性缺血性脑卒中110例[J].青岛医药卫生，2014，46（3）：216-218.
[7] 马春玲.尼莫地平辅助治疗对急性缺血性脑卒中患者神经保护作用的影响[J].中国当代医药，2013，20（25）：79-82.
[8] 田治友.早期应用尼莫地平治疗脑卒中后抑郁症疗效分析[J].中国实用神经疾病杂志，2013，16（23）：35-36.
[9] 李和平，吴丽娥.丁苯酞对急性缺血性脑卒中的作用及保护机制[J].中华脑血管病杂志，2013，7（6）：342-345.
[10] 李延可，刘宁，陈江君.丁苯酞对急性缺血性脑卒中的作用及机制研究[J].中国医药导刊，2012，14（2）：254-255.
[11] 许莹，马英.丁苯酞氯化钠治疗急性缺血性脑卒中的临床研究[J].实用药物与临床2015，18（5）：559-562.
[12] 马荣芳，江玉玲.丁苯酞治疗急性缺血性脑卒中患者的临床效果及对其hs-CRP的影响[J].中国实用医刊，2015， 42（14）：58-59.
[13] 鲁文琴，尹航.盐酸氟桂利嗪胶囊的临床研究与药理作用[J].中国现代药物应用，2012，6（19）：130-131.
[14] 王大伟.盐酸氟桂利嗪辅助治疗急性脑梗死的临床效果[J].中国实用医药，2014，9（30）：144-145.
[15] 邸红岩，苏民，赵受伟.穴位注射鼠神经生长因子对脑卒中患者临床疗效观察[J].齐齐哈尔医学院学报，2014， 35（11）：1568-1569.
[16] 胡建方，张明艳，谭洁，等.鼠神经生长因子联合生物反馈治疗脑卒中偏瘫疗效观察[J].浙江临床医学，2013， 15（11）：1630-1639.
[17] 袁婷，何琪.鼠神经生长因子注射液联合奥拉西坦注射液对脑卒中患者的疗效研究[J].中国当代医药，2012， 19（35）：16-20.
[18] 刘楠，张微微，魏微，等.长春西汀（开文通）治疗急性脑梗死的疗效与安全性的临床研究[J].中华神经医学杂志，2014，13（3）：273-276.
[19] Patyar S，Prakash A，Modi M，et al.Role of vinpocetine in cerebrovascular diseases [J]. Pharmacol Rep，2011，63（3）：618-628.
[20] Zhang LJ，Li Y. Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke：a review of the literature [J]. Molecules，2015，20：335-347.
[21] 罗海龙.奥扎格雷钠联合长春西汀治疗进展性脑卒中的效果及对血小板活化的作用[J].临床医学工程，2015， 22（4）：465-466.
[22] 车雁芳，杨国华，师春梅，等.长春西汀联合奥扎格雷钠治疗进展性缺血性脑卒中临床疗效及其对血小板活化的影响[J].黑龙江医学，2015，39（4）：390-392. |
|
|
|
